Rationale and design of a randomized controlled trial of directly observed hepatitis C treatment delivered in methadone clinics
Most methadone-maintained injection drug users (IDUs) have been infected with hepatitis C virus (HCV), but few initiate HCV treatment. Physicians may be reluctant to treat HCV in IDUs because of concerns about treatment adherence, psychiatric comorbidity, or ongoing drug use.
Optimal HCV management approaches for IDUs remain unknown. We are conducting a randomized controlled trial in a network of nine methadone clinics with onsite HCV care to determine whether modified directly observed therapy (mDOT), compared to treatment as usual (TAU), improves adherence and virologic outcomes among opioid users.
Methods:
We plan to enroll 80 HCV-infected adults initiating care with pegylated interferon alfa-2a (IFN) plus ribavirin, and randomize them to mDOT (directly observed daily ribavirin plus provider-administered weekly IFN) or TAU (self-administered ribavirin plus provider-administered weekly IFN).
Our outcome measures are: 1) self-reported and pill count adherence, and 2) end of treatment response (ETR) or sustained viral response (SVR). We will use mixed effects linear models to assess differences in pill count adherence between treatment arms (mDOT v.
TAU), and we will assess differences between treatment arms in the proportion of subjects with ETR or SVR with chi square tests. Of the first 40 subjects enrolled: 21 have been randomized to mDOT and 19 to TAU.
To date, the sample is 77% Latino, 60% HCV genotype-1, 38% active drug users, and 27% HIV-infected. Our overall retention rate at 24 weeks is 92%, 93% in the mDOT arm and 92% in the TAU arm.DiscussionThis paper describes the design and rationale of a randomized clinical trial comparing modified directly observed HCV therapy delivered in a methadone program to on-site treatment as usual.
Our trial will allow rigorous evaluation of the efficacy of directly observed HCV therapy (both pegylated interferon and ribavirin) for improving adherence and clinical outcomes. This detailed description of trial methodology can serve as a template for the development of future DOT programs, and can also guide protocols for studies among HCV-infected drug users receiving methadone for opiate dependence.Trial Registration: ClinicalTrials.gov: NCT01442311
Author: Alain LitwinKarina BergXuan LiJennifer HidalgoJulia Arnsten
Credits/Source: BMC Infectious Diseases 2011, 11:315
Published on: 2011-11-12
Copyright by the authors listed above - made available via BioMedCentral (Open Access). Please
make sure to read our disclaimer prior to contacting 7thSpace Interactive. To contact our editors, visit our online helpdesk. If you wish submit your own press release, click here.
Social Bookmarking
RETWEET This! | Digg this! | Post to del.icio.us | Post to Furl | Add to Netscape | Add to Yahoo! | Rojo
|
|
herpes, HPV, hepatitis and other STDs. Find friendship, support, and even love
with STD here!
STDsMatch...C óM --The best, most trusted and largest dating site for black
people who with STD in the world! There will be lots of potential soulmates .
The site offers live STD counseling, STD questions and answer,member
verification (age, income, etc), member blogs, chatting services and more.
believe me. But the truth is that this site has more than 1,880,000 members and about 80% members are good looking in my estimation.
Unfortunately, STD rates soar worldwide and most people with STDs don't even know that they have them. So do use a condom to protect yourself!!!!
The government should grant more money for STD education to lower the rates of STD transmission.